Free Trial
→ SpaceX eyes a 1.75 trillion valuation - here's what to know (From Brownstone Research) (Ad)tc pixel Free CYCC Stock Alerts

This company has been marked as potentially delisted and may not be actively trading.

Cyclacel Pharmaceuticals (CYCC) Competitors

Cyclacel Pharmaceuticals logo
Compare

CYCC vs. PYRGF, MGX, ANVS, INKT, and TIL

Should you be buying Cyclacel Pharmaceuticals stock or one of its competitors? The main competitors of Cyclacel Pharmaceuticals include PyroGenesis Canada (PYRGF), Metagenomi (MGX), Annovis Bio (ANVS), MiNK Therapeutics (INKT), and Instil Bio (TIL). These companies are all part of the "pharmaceutical products" industry.

How does Cyclacel Pharmaceuticals compare to PyroGenesis Canada?

Cyclacel Pharmaceuticals (NASDAQ:CYCC) and PyroGenesis Canada (NASDAQ:PYRGF) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, risk, profitability, earnings, media sentiment and analyst recommendations.

Cyclacel Pharmaceuticals has a beta of 0.15, meaning that its stock price is 85% less volatile than the S&P 500. Comparatively, PyroGenesis Canada has a beta of 0.26, meaning that its stock price is 74% less volatile than the S&P 500.

Cyclacel Pharmaceuticals has higher earnings, but lower revenue than PyroGenesis Canada. PyroGenesis Canada is trading at a lower price-to-earnings ratio than Cyclacel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cyclacel Pharmaceuticals$40K356.44-$11.21M-$839.58N/A
PyroGenesis Canada$9.14M6.83-$21.12M-$0.05N/A

23.6% of Cyclacel Pharmaceuticals shares are owned by institutional investors. Comparatively, 0.0% of PyroGenesis Canada shares are owned by institutional investors. 51.2% of Cyclacel Pharmaceuticals shares are owned by insiders. Comparatively, 47.7% of PyroGenesis Canada shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, PyroGenesis Canada had 1 more articles in the media than Cyclacel Pharmaceuticals. MarketBeat recorded 1 mentions for PyroGenesis Canada and 0 mentions for Cyclacel Pharmaceuticals. Cyclacel Pharmaceuticals' average media sentiment score of 0.00 equaled PyroGenesis Canada'saverage media sentiment score.

Company Overall Sentiment
Cyclacel Pharmaceuticals Neutral
PyroGenesis Canada Neutral

Cyclacel Pharmaceuticals has a net margin of 0.00% compared to PyroGenesis Canada's net margin of -115.14%. PyroGenesis Canada's return on equity of 0.00% beat Cyclacel Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Cyclacel PharmaceuticalsN/A -723.64% -145.51%
PyroGenesis Canada -115.14%N/A -60.81%

Summary

Cyclacel Pharmaceuticals and PyroGenesis Canada tied by winning 6 of the 12 factors compared between the two stocks.

How does Cyclacel Pharmaceuticals compare to Metagenomi?

Metagenomi (NASDAQ:MGX) and Cyclacel Pharmaceuticals (NASDAQ:CYCC) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, risk, dividends and valuation.

Metagenomi has a beta of 0.63, suggesting that its stock price is 37% less volatile than the S&P 500. Comparatively, Cyclacel Pharmaceuticals has a beta of 0.15, suggesting that its stock price is 85% less volatile than the S&P 500.

Metagenomi currently has a consensus price target of $10.00, indicating a potential upside of 599.30%. Given Metagenomi's stronger consensus rating and higher probable upside, research analysts clearly believe Metagenomi is more favorable than Cyclacel Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Metagenomi
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.80
Cyclacel Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Cyclacel Pharmaceuticals has lower revenue, but higher earnings than Metagenomi. Metagenomi is trading at a lower price-to-earnings ratio than Cyclacel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Metagenomi$25.21M2.14-$87.87M-$2.37N/A
Cyclacel Pharmaceuticals$40K356.44-$11.21M-$839.58N/A

23.6% of Cyclacel Pharmaceuticals shares are held by institutional investors. 17.8% of Metagenomi shares are held by company insiders. Comparatively, 51.2% of Cyclacel Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Metagenomi had 1 more articles in the media than Cyclacel Pharmaceuticals. MarketBeat recorded 1 mentions for Metagenomi and 0 mentions for Cyclacel Pharmaceuticals. Metagenomi's average media sentiment score of 0.00 equaled Cyclacel Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Metagenomi Neutral
Cyclacel Pharmaceuticals Neutral

Cyclacel Pharmaceuticals has a net margin of 0.00% compared to Metagenomi's net margin of -348.54%. Metagenomi's return on equity of -47.14% beat Cyclacel Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Metagenomi-348.54% -47.14% -33.82%
Cyclacel Pharmaceuticals N/A -723.64%-145.51%

Summary

Metagenomi beats Cyclacel Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does Cyclacel Pharmaceuticals compare to Annovis Bio?

Annovis Bio (NYSE:ANVS) and Cyclacel Pharmaceuticals (NASDAQ:CYCC) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, dividends, media sentiment, institutional ownership, risk and earnings.

15.8% of Annovis Bio shares are held by institutional investors. Comparatively, 23.6% of Cyclacel Pharmaceuticals shares are held by institutional investors. 20.8% of Annovis Bio shares are held by company insiders. Comparatively, 51.2% of Cyclacel Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Annovis Bio has a beta of 1.26, indicating that its stock price is 26% more volatile than the S&P 500. Comparatively, Cyclacel Pharmaceuticals has a beta of 0.15, indicating that its stock price is 85% less volatile than the S&P 500.

In the previous week, Annovis Bio's average media sentiment score of 0.00 equaled Cyclacel Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Annovis Bio Neutral
Cyclacel Pharmaceuticals Neutral

Annovis Bio's return on equity of -159.43% beat Cyclacel Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Annovis BioN/A -159.43% -133.49%
Cyclacel Pharmaceuticals N/A -723.64%-145.51%

Cyclacel Pharmaceuticals has higher revenue and earnings than Annovis Bio. Annovis Bio is trading at a lower price-to-earnings ratio than Cyclacel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Annovis BioN/AN/A-$28.85M-$1.40N/A
Cyclacel Pharmaceuticals$40K356.44-$11.21M-$839.58N/A

Annovis Bio presently has a consensus price target of $13.50, suggesting a potential upside of 463.67%. Given Annovis Bio's stronger consensus rating and higher probable upside, equities analysts clearly believe Annovis Bio is more favorable than Cyclacel Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Annovis Bio
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25
Cyclacel Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Summary

Annovis Bio beats Cyclacel Pharmaceuticals on 7 of the 12 factors compared between the two stocks.

How does Cyclacel Pharmaceuticals compare to MiNK Therapeutics?

MiNK Therapeutics (NASDAQ:INKT) and Cyclacel Pharmaceuticals (NASDAQ:CYCC) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, dividends, media sentiment, institutional ownership, risk and earnings.

MiNK Therapeutics presently has a consensus price target of $35.00, suggesting a potential upside of 212.22%. Given MiNK Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe MiNK Therapeutics is more favorable than Cyclacel Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MiNK Therapeutics
1 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.40
Cyclacel Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

MiNK Therapeutics has a beta of 0.47, indicating that its stock price is 53% less volatile than the S&P 500. Comparatively, Cyclacel Pharmaceuticals has a beta of 0.15, indicating that its stock price is 85% less volatile than the S&P 500.

In the previous week, MiNK Therapeutics had 1 more articles in the media than Cyclacel Pharmaceuticals. MarketBeat recorded 1 mentions for MiNK Therapeutics and 0 mentions for Cyclacel Pharmaceuticals. MiNK Therapeutics' average media sentiment score of 0.51 beat Cyclacel Pharmaceuticals' score of 0.00 indicating that MiNK Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
MiNK Therapeutics Positive
Cyclacel Pharmaceuticals Neutral

2.9% of MiNK Therapeutics shares are held by institutional investors. Comparatively, 23.6% of Cyclacel Pharmaceuticals shares are held by institutional investors. 22.5% of MiNK Therapeutics shares are held by company insiders. Comparatively, 51.2% of Cyclacel Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Cyclacel Pharmaceuticals has higher revenue and earnings than MiNK Therapeutics. MiNK Therapeutics is trading at a lower price-to-earnings ratio than Cyclacel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MiNK TherapeuticsN/AN/A-$12.49M-$2.97N/A
Cyclacel Pharmaceuticals$40K356.44-$11.21M-$839.58N/A

MiNK Therapeutics' return on equity of 0.00% beat Cyclacel Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
MiNK TherapeuticsN/A N/A -139.00%
Cyclacel Pharmaceuticals N/A -723.64%-145.51%

Summary

MiNK Therapeutics beats Cyclacel Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

How does Cyclacel Pharmaceuticals compare to Instil Bio?

Cyclacel Pharmaceuticals (NASDAQ:CYCC) and Instil Bio (NASDAQ:TIL) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, profitability, risk, analyst recommendations, media sentiment, institutional ownership, dividends and earnings.

Instil Bio has a consensus price target of $66.00, suggesting a potential upside of 723.97%. Given Instil Bio's stronger consensus rating and higher probable upside, analysts clearly believe Instil Bio is more favorable than Cyclacel Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cyclacel Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Instil Bio
1 Sell rating(s)
3 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.75

Cyclacel Pharmaceuticals has a beta of 0.15, suggesting that its share price is 85% less volatile than the S&P 500. Comparatively, Instil Bio has a beta of 1.94, suggesting that its share price is 94% more volatile than the S&P 500.

In the previous week, Cyclacel Pharmaceuticals' average media sentiment score of 0.00 equaled Instil Bio'saverage media sentiment score.

Company Overall Sentiment
Cyclacel Pharmaceuticals Neutral
Instil Bio Neutral

23.6% of Cyclacel Pharmaceuticals shares are held by institutional investors. Comparatively, 60.6% of Instil Bio shares are held by institutional investors. 51.2% of Cyclacel Pharmaceuticals shares are held by company insiders. Comparatively, 47.0% of Instil Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Cyclacel Pharmaceuticals has higher revenue and earnings than Instil Bio. Instil Bio is trading at a lower price-to-earnings ratio than Cyclacel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cyclacel Pharmaceuticals$40K356.44-$11.21M-$839.58N/A
Instil BioN/AN/A-$71.37M-$10.78N/A

Instil Bio's return on equity of -55.88% beat Cyclacel Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Cyclacel PharmaceuticalsN/A -723.64% -145.51%
Instil Bio N/A -55.88%-32.31%

Summary

Instil Bio beats Cyclacel Pharmaceuticals on 7 of the 11 factors compared between the two stocks.

Get Cyclacel Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for CYCC and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CYCC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CYCC vs. The Competition

Export
MetricCyclacel PharmaceuticalsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$14.26M$3.40B$6.28B$11.90B
Dividend YieldN/A2.23%2.74%5.26%
P/E Ratio-0.0138.9429.1827.35
Price / Sales356.44309.34507.9485.59
Price / CashN/A125.3043.4254.56
Price / Book-0.117.379.856.79
Net Income-$11.21M$23.57M$3.55B$332.68M

Cyclacel Pharmaceuticals Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CYCC
Cyclacel Pharmaceuticals
N/A$6.37
flat		N/AN/A$14.26M$40KN/A14
PYRGF
PyroGenesis Canada
N/A$0.28
-6.0%		N/A-7.2%$56.82M$9.14MN/A90
MGX
Metagenomi
2.2991 of 5 stars		$1.44
-2.7%		$10.00
+594.4%		-1.0%$55.68M$25.21MN/A236
ANVS
Annovis Bio
2.2155 of 5 stars		$1.88
-0.8%		$13.50
+620.0%		+65.7%$55.32MN/AN/A3
INKT
MiNK Therapeutics
2.9575 of 5 stars		$10.88
-2.3%		$35.00
+221.7%		+47.0%$55.32MN/AN/A30

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:CYCC) was last updated on 5/7/2026 by MarketBeat.com Staff.
From Our Partners
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
Sell 99% of Your Stocks, Do THIS Instead…
Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...
The Oxford Club | Sponsoredtc pixel
Trade this between 9:30 and 10:45 am EST
The first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Elon Unveils AI Passive Income Stream for Millions of Americans
During Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...
InvestorPlace | Sponsoredtc pixel
Invest in SpaceX Before IPO
SpaceX is already one of the most valuable private companies on Earth, and some analysts believe its valuation...
NXT Wave Research | Sponsoredtc pixel
Satellite Images Spot Potential $10 Trillion Discovery
'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...
Altimetry | Sponsoredtc pixel